Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts Sells 600 Shares

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $287.43, for a total value of $172,458.00. Following the transaction, the executive vice president now owns 66,539 shares in the company, valued at approximately $19,125,304.77. This represents a 0.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Penumbra Stock Performance

PEN stock opened at $285.91 on Thursday. The company has a market cap of $11.01 billion, a P/E ratio of 840.91, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The stock’s fifty day moving average price is $265.94 and its 200-day moving average price is $234.26.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. The firm had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. On average, equities analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Hedge Funds Weigh In On Penumbra

A number of institutional investors have recently bought and sold shares of PEN. True Wealth Design LLC bought a new position in Penumbra in the 3rd quarter worth $26,000. UMB Bank n.a. raised its holdings in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after purchasing an additional 70 shares during the period. Hurley Capital LLC bought a new position in Penumbra in the 4th quarter worth $56,000. Huntington National Bank raised its holdings in Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after purchasing an additional 154 shares during the period. Finally, Mather Group LLC. raised its holdings in Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after purchasing an additional 208 shares during the period. 88.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PEN. JPMorgan Chase & Co. boosted their price target on Penumbra from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. BTIG Research lifted their price objective on Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Wells Fargo & Company lifted their price objective on Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Piper Sandler reaffirmed an “overweight” rating and set a $330.00 price objective (up from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada lifted their price objective on Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $292.64.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.